S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
NASDAQ:KPRX

Kiora Pharmaceuticals (KPRX) Stock Price, News & Analysis

$0.71
+0.09 (+14.61%)
(As of 03/28/2024 ET)
Today's Range
$0.60
$0.72
50-Day Range
$0.55
$0.85
52-Week Range
$0.46
$5.25
Volume
600,819 shs
Average Volume
167,370 shs
Market Capitalization
$5.43 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

Kiora Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
891.5% Upside
$7.00 Price Target
Short Interest
Healthy
1.18% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.25mentions of Kiora Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.34 out of 5 stars

KPRX stock logo

About Kiora Pharmaceuticals Stock (NASDAQ:KPRX)

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

KPRX Stock Price History

KPRX Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 3.8%
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Kiora Pharmaceuticals Inc KPRX
Kiora Pharmaceuticals reports Q3 results
Analyst Expectations for Kiora Pharmaceuticals's Future
See More Headlines
Receive KPRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Kiora Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
3/29/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:KPRX
Fax
N/A
Employees
12
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$7.00
High Stock Price Target
$7.00
Low Stock Price Target
$7.00
Potential Upside/Downside
+891.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-13,580,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.99 per share

Miscellaneous

Free Float
7,617,000
Market Cap
$5.43 million
Optionable
Not Optionable
Beta
-0.28
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Brian M. Strem Ph.D. (Age 44)
    President, CEO & Director
    Comp: $464.93k
  • Ms. Melissa Tosca CPA (Age 44)
    Executive Vice President of Finance
    Comp: $282.28k
  • Dr. Eric J. Daniels M.B.A. (Age 50)
    M.D., Chief Development Officer
    Comp: $371.47k
  • Dr. Stefan Sperl Ph.D.
    Executive Vice President of CMC & Operations

KPRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Kiora Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kiora Pharmaceuticals in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KPRX shares.
View KPRX analyst ratings
or view top-rated stocks.

What is Kiora Pharmaceuticals' stock price target for 2024?

1 Wall Street research analysts have issued 1-year target prices for Kiora Pharmaceuticals' shares. Their KPRX share price targets range from $7.00 to $7.00. On average, they predict the company's share price to reach $7.00 in the next twelve months. This suggests a possible upside of 891.5% from the stock's current price.
View analysts price targets for KPRX
or view top-rated stocks among Wall Street analysts.

How have KPRX shares performed in 2024?

Kiora Pharmaceuticals' stock was trading at $0.5224 at the start of the year. Since then, KPRX shares have increased by 35.1% and is now trading at $0.7060.
View the best growth stocks for 2024 here
.

Are investors shorting Kiora Pharmaceuticals?

Kiora Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 86,400 shares, an increase of 51.6% from the February 29th total of 57,000 shares. Based on an average daily trading volume, of 1,560,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 1.2% of the company's shares are short sold.
View Kiora Pharmaceuticals' Short Interest
.

When is Kiora Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our KPRX earnings forecast
.

How were Kiora Pharmaceuticals' earnings last quarter?

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) released its quarterly earnings data on Monday, November, 15th. The company reported ($11.60) EPS for the quarter, beating the consensus estimate of ($13.48) by $1.88.

When did Kiora Pharmaceuticals' stock split?

Kiora Pharmaceuticals shares reverse split on the morning of Tuesday, September 27th 2022. The 1-40 reverse split was announced on Tuesday, September 27th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, September 27th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Who are Kiora Pharmaceuticals' major shareholders?

Kiora Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Citadel Advisors LLC (1.20%).

How do I buy shares of Kiora Pharmaceuticals?

Shares of KPRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:KPRX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners